Eating Disorders and GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications
originally developed to treat type 2 diabetes. GLP-1 RAs are now being used as an approved or off-label treatment for weight loss and have been trialled as a treatment for some eating disorders such as binge eating disorder (BED).

There is limited research available to help researchers, clinicians and patients/consumers to understand 
the relationships between GLP-1 RAs and eating disorders. However, it is thought that GLP-1 RAs may 
negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information about GLP-1 RAs as well as their possible interaction with eating disorders including physical and psychological impacts. Practice points are provided for clinicians.


« Back to Browse Resources

See also

Stepped System of Care - Greek

Η National Eating Disorders Collaboration (NEDC) έχει ενσωματώσει δύο δεκαετίες συναίνεσης τομεακών και βιωμένων εμπειριών και ανάπτυξης υπηρεσιών στο μοντέλο του σταδιακού συστήματος περίθαλψης για τις διατροφικές διαταχές (Εικόνα 1η).

Read more

Eating Disorders Information and Support for Australians – Resource Review 

In recognition that body image and Eating Disorders are a pressing issue within the Australian community, the Commonwealth of Australia commissioned this report to be prepared by the Butterfly Foundation (“Butterfly”) on behalf of the National Eating Disorders Collaboration (NEDC).

Read more

7 Tips for Improving Your Body Image

Click here to download full size

Read more

NEDC Fact Sheet - Cognitive Behavioural Therapy Guided Self Help (CBT-GSH)

This resource is for GPs and health professionals who are seeking a better understanding of Cognitive Behavioural Therapy Guided Self Help (CBT-GSH) in eating disorders, and their role in using this as a treatment in some eating disorder presentations.

Read more